Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Vertex Pharmaceuticals logoVertex Pharmaceuticals VRTX

The company said its board authorized an additional program to repurchase up to $4.0 billion of its common stock (the 2025 Repurchase Program).

8-KOther EventsFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said its board authorized an additional program to repurchase up to $4.0 billion of its common stock (the 2025 Repurchase Program).

  2. The company said the 2025 Repurchase Program has no expiration date and can be discontinued at any time.

  3. Vertex said it may repurchase shares from time to time, subject to general business and market conditions and other investment opportunities, on the open market or in privately negotiated transactions, including under Rule 10b5-1 plans.

  4. The company said that, under the 2023 authorized $3.0 billion 2023 Repurchase Program, approximately $775 million remained available as of May 16, 2025, and that the two programs together authorize repurchases of up to $4.775 billion.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Vertex Authorizes $4.0 billion 2025 Repurchase Program

The company said its board authorized an additional program to repurchase up to $4.0 billion of its common stock (the 2025 Repurchase Program).

Source · Based on the filing body and exhibits

Expiration and Discontinuation Terms of the 2025 Repurchase Program

The company said the 2025 Repurchase Program has no expiration date and can be discontinued at any time.

Source · Based on the filing body and exhibits

Repurchase Methods and Conditions

Vertex said it may repurchase shares from time to time, subject to general business and market conditions and other investment opportunities, on the open market or in privately negotiated transactions, including under Rule 10b5-1 plans.

Source · Based on the filing body and exhibits

Remaining Capacity and Combined Limit Under the 2023 Repurchase Program

The company said that, under the 2023 authorized $3.0 billion 2023 Repurchase Program, approximately $775 million remained available as of May 16, 2025, and that the two programs together authorize repurchases of up to $4.775 billion.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.